Abstract:"Functional cure" is being pursued as the ultimate endpoint of antiviral treatment in chronic hepatitis B (CHB), which is characterized by loss of HBsAg whether or not anti-HBs antibodies are present. "Functional cure" can be achieved in <10% of CHB patients with currently available therapeutic agents. The dysfunction of specific immune responses to hepatitis B virus (HBV) is considered the major cause of persistent HBV infection. Thus, modulating the host immune system to strengthen specific cellular immune reactions might help eliminate HBV. Strategies are needed to restore/enhance innate immunity and induce HBV-specific adaptive immune responses in a coordinated way. Immune and resident cells express pattern recognition receptors like TLRs and RIG I/MDA5, which play important roles in the induction of innate immunity through sensing of pathogen-associated molecular patterns (PAMPs) and bridging to adaptive immunity for pathogen-specific immune control. TLR/RIG I agonists activate innate immune responses and suppress HBV replication in vitro and in vivo, and are being investigated in clinical trials. On the other hand, HBV-specific immune responses could be induced by therapeutic vaccines, including protein (HBsAg/preS and HBcAg), DNA, and viral vector-based vaccines. More than 50 clinical trials have been performed to assess therapeutic vaccines in CHB treatment, some of which display potential effects. Most recently, using genetic editing technology to generate CAR-T or TCR-T, HBV-specific T cells have been produced to efficiently clear HBV. This review summarizes the progress in basic and clinical research investigating immunomodulatory strategies for curing chronic HBV infection, and critically discusses the rather disappointing results of current clinical trials and future strategies.

Progress in therapeutic monoclonal antibodies targeting hepatitis B surface antigen

Antibody-mediated immunotherapy against chronic hepatitis B virus infection.

Development of monoclonal antibodies to target the large surface protein of hepatitis B virus and their use in therapeutic and diagnostic applications

New advances in drug therapy of chronic hepatitis B infection

Current trends and advances in antiviral therapy for chronic hepatitis B

Development of monoclonal antibodies against PD-L1 and preliminary investigation on potential application in treatment of chronic hepatitis B virus in-fection

Anti-Hbv Drugs: Progress, Unmet Needs, and New Hope

New anti-hepatitis B virus drugs under development and evaluation.

Humanization of Therapeutic Antibody of One Hepatitis B Virus and Identification of Its Biological Activity

Advances in Targeting the Innate and Adaptive Immune Systems to Cure Chronic Hepatitis B Virus Infection

Development of novel therapeutics for chronic hepatitis B

Toward a Functional Cure for Hepatitis B: the Rationale and Challenges for Therapeutic Targeting of the B Cell Immune Response

New Anti-Hepatitis B Virus Drugs under Development and Evaluation

Advances in determining new treatments for hepatitis B infection by utilizing existing and novel biomarkers

Prolonged suppression of HBV in mice by a novel antibody that targets a unique epitope on hepatitis B surface antigen

Current and future use of antibody-based passive immunity to prevent or control HBV/HDV infections.

Hepatitis B surface antigen and functional cure of chronic hepatitis B

A broad-spectrum nanobody targeting the C-terminus of the hepatitis B surface antigen for chronic hepatitis B infection therapy

A Dual‐domain Engineered Antibody for Efficient HBV Suppression and Immune Responses Restoration

TCR-like bispecific antibodies toward eliminating infected hepatocytes in HBV mouse models

Present and Future Therapies for Chronic Hepatitis B.